Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Repurchased Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Lisata Therapeutics (LSTA) Long-Term Debt Issuances (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Long-Term Debt Issuances readings, the most recent being $2.0 for Q4 2017.

For the quarter ending Q4 2017, Long-Term Debt Issuances fell 100.0% year-over-year to $2.0, compared with a TTM value of $2.0 through Sep 2018, down 100.0%, and an annual FY2017 reading of $401000.0, down 50.09% over the prior year.
Long-Term Debt Issuances hit $2.0 in Q4 2017 for Lisata Therapeutics, down from $400998.0 in the prior quarter.
The five-year high for Long-Term Debt Issuances was $1.0 million in Q4 2013, with the low at -$221218.0 in Q3 2013.
Median Long-Term Debt Issuances over the past 5 years was $375791.0 (2014), compared with a mean of $368615.6.
The sharpest move saw Long-Term Debt Issuances surged 566.07% in 2013, then plummeted 100.52% in 2015.
Year by year, Long-Term Debt Issuances stood at $1.0 million in 2013, then crashed by 95.17% to $50250.0 in 2014, then tumbled by 104.48% to -$2250.0 in 2015, then surged by 19428.13% to $434883.0 in 2016, then crashed by 100.0% to $2.0 in 2017.
According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at $2.0, $400998.0, and $434883.0 for Q4 2017, Q1 2017, and Q4 2016 respectively.